Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | BLVRB | P30043 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316934 | 0.80 | PTGS2 (0.48) | MAPTALDH1A1KDM4ETDP1L3MBTL1 | |
| SCHEMBL13658553 | 0.80 | CA1 (0.42) | MAPTALDH1A1KDM4ETDP1L3MBTL1 | |
| SCHEMBL3070179 | 0.78 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ETDP1L3MBTL1 | |
| SCHEMBL19720102 | 0.76 | ALDH1A1 (0.33) | MAPTALDH1A1KDM4ETDP1HSD17B10 | |
| SCHEMBL7188467 | 0.74 | GAA (0.47) | MAPTALDH1A1KDM4ETDP1HSD17B10 | |
| SCHEMBL18403872 | 0.74 | ALOX15 (0.50) | ALDH1A1HSD17B10MEN1KMT2AHTT | |
| SCHEMBL798232 | 0.74 | HSD17B10 (0.41) | MAPTALDH1A1KDM4EHSD17B10MEN1 | |
| SCHEMBL639211 | 0.74 | RAB9A (0.52) | MAPTALDH1A1KDM4ETDP1NPC1 | |
| SCHEMBL11213671 | 0.74 | PTGS1 (0.53) | MAPTALDH1A1TDP1L3MBTL1NPC1 | |
| SCHEMBL2185973 | 0.74 | ALOX15 (0.50) | MAPTALDH1A1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107649101-A | Mercapto-functionalized titania molecule trace composite and its aqueous phase preparation method and application | 湖南大学 | 2018-02-02 | — | — | CN | claimed |
| CN-106661074-A | Synthesis of phosphoramidates | 桑多斯股份公司 | 2017-05-10 | — | — | CN | claimed |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20200093831-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | MITOCHON PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | US | disclosed |
| US-10457629-B2 | Therapeutic DNP derivatives and methods using same | YALE UNIVERSITY (US) | 2019-10-29 | — | — | US | disclosed |
| CN-110369482-A | A kind of method of repairing environment hormone contaminated soil | 湖南工业大学 | 2019-10-25 | — | — | CN | disclosed |
| CN-109022292-A | One plant of trichoderma and its application in agriculture field | 慕恩（广州）生物科技有限公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-104837863-B | Proteolytic inactivation of selected proteins in bacterial extracts for enhanced expression | 苏特罗生物制药公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-107649101-A | Mercapto-functionalized titania molecule trace composite and its aqueous phase preparation method and application | 湖南大学 | 2018-02-02 | — | — | CN | disclosed |
| CN-107602449-A | A kind of preparation and application of the Zn complex fluorescence probe with graphite-like structure | 常州工程职业技术学院 | 2018-01-19 | — | — | CN | disclosed |
| CN-105801440-B | A kind of preparation method of the nitrophenol of 2 amino 4 | 江苏安诺其化工有限公司 | 2017-11-21 | — | — | CN | disclosed |
| CN-107253914-A | The method that the nitrophenol of 2 amino 4 is prepared using Disperse Blue 2BLN byproduct | 青岛海湾集团有限公司 | 2017-10-17 | — | — | CN | disclosed |
| CN-106573084-A | Wetness indicator with permanent colorant | 宝洁公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20120264739-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-10-18 | — | — | US | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093831-A1 | DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases | SMN1; SMN2, MYLK2, WFS1 | MAPT 1834/4885ALDH1A1 2044/4885KDM4E 2539/4885 |
| US-20120264739-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | MAPT 3267/4885ALDH1A1 337/4885KDM4E 4236/4885 |
| US-10457629-B2 | Therapeutic DNP derivatives and methods using same | DNPEP, NPPA, DNPH1 | MAPT 1255/4885ALDH1A1 524/4885KDM4E 1912/4885 |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | MAPT 4161/4885ALDH1A1 2383/4885KDM4E 4417/4885 |
| US-11406642-B2 | DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases | SMN1; SMN2, MYLK2, WFS1 | MAPT 1834/4885ALDH1A1 2044/4885KDM4E 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.